WallStSmart

Boston Scientific Corp (BSX)vsiRhythm Technologies Inc (IRTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 2587% more annual revenue ($20.07B vs $747.14M). BSX leads profitability with a 14.4% profit margin vs -6.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

IRTC

Avoid

31

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.31
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for IRTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

IRTC1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
27.1%8/10

Revenue surging 27.1% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

IRTC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
4.2%3/10

Operating margin of 4.2%

Price/BookValuation
25.7x2/10

Trading at 25.7x book value

Return on EquityProfitability
-36.6%2/10

ROE of -36.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : IRTC

The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 27.1% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : IRTC

The primary concerns for IRTC are EPS Growth, Operating Margin, Price/Book.

Key Dynamics to Monitor

IRTC carries more volatility with a beta of 1.15 — expect wider price swings.

IRTC is growing revenue faster at 27.1% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 31/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

iRhythm Technologies Inc

HEALTHCARE · MEDICAL DEVICES · USA

iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.

Want to dig deeper into these stocks?